Two Sigma Investments LP Invests $16.04 Million in The Clorox Company (NYSE:CLX)

Two Sigma Investments LP purchased a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 98,765 shares of the company's stock, valued at approximately $16,040,000. Two Sigma Investments LP owned 0.08% of Clorox at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Tidal Investments LLC grew its position in Clorox by 5.9% during the fourth quarter. Tidal Investments LLC now owns 31,665 shares of the company's stock valued at $5,143,000 after acquiring an additional 1,752 shares during the period. Teza Capital Management LLC grew its position in Clorox by 766.4% during the fourth quarter. Teza Capital Management LLC now owns 13,741 shares of the company's stock valued at $2,232,000 after acquiring an additional 12,155 shares during the period. Tang Capital Management LLC grew its position in Clorox by 386.6% during the fourth quarter. Tang Capital Management LLC now owns 6,014 shares of the company's stock valued at $977,000 after acquiring an additional 4,778 shares during the period. Studio Investment Management LLC grew its position in Clorox by 67.7% during the fourth quarter. Studio Investment Management LLC now owns 4,309 shares of the company's stock valued at $700,000 after acquiring an additional 1,740 shares during the period. Finally, Siemens Fonds Invest GmbH grew its position in Clorox by 584.8% during the fourth quarter. Siemens Fonds Invest GmbH now owns 8,895 shares of the company's stock valued at $1,445,000 after acquiring an additional 7,596 shares during the period. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Stock Up 0.4%

Shares of Clorox stock traded up $0.57 during trading on Wednesday, reaching $130.93. The company had a trading volume of 319,621 shares, compared to its average volume of 1,333,471. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The firm's fifty day moving average is $139.05 and its 200-day moving average is $151.85. The company has a market cap of $16.14 billion, a price-to-earnings ratio of 35.78, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60.

Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). Clorox had a net margin of 6.38% and a return on equity of 316.87%. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the prior year, the firm earned $1.71 earnings per share. The firm's quarterly revenue was down 8.0% compared to the same quarter last year. On average, analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Insider Transactions at Clorox

In other news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the transaction, the director now owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.57% of the company's stock.

Analysts Set New Price Targets

CLX has been the subject of a number of research reports. Citigroup lowered their price target on Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research report on Monday, April 14th. Wells Fargo & Company decreased their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $150.00 target price on shares of Clorox in a research report on Thursday, January 30th. JPMorgan Chase & Co. decreased their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Finally, Morgan Stanley decreased their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.